Literature DB >> 21805646

Synthesis and antitumor molecular mechanism of agents based on amino 2-(3',4',5'-trimethoxybenzoyl)benzo[b]furan: inhibition of tubulin and induction of apoptosis.

Romeo Romagnoli1, Pier Giovanni Baraldi, Carlota Lopez-Cara, Olga Cruz-Lopez, Maria Dora Carrion, Maria Kimatrai Salvador, Jaime Bermejo, Sara Estévez, Francisco Estévez, Jan Balzarini, Andrea Brancale, Antonio Ricci, Longchuan Chen, Jae Gwan Kim, Ernest Hamel.   

Abstract

Induction of apoptosis is a promising strategy that could lead to the discovery of new molecules active in cancer chemotherapy. This property is generally observed when cells are treated with agents that target microtubules, dynamic structures that play a crucial role in cell division. Small molecules such as benzo[b]furans are attractive as inhibitors of tubulin polymerization. A new class of inhibitors of tubulin polymerization based on the 2-(3',4',5'-trimethoxybenzoyl)benzo[b]furan molecular skeleton, with the amino group placed at different positions on the benzene ring, were synthesized and evaluated for antiproliferative activity, inhibition of tubulin polymerization, and cell-cycle effects. The methoxy substitution pattern on the benzene portion of the benzo[b]furan moiety played an important role in affecting antiproliferative activity. In the series of 5-amino derivatives, the greatest inhibition of cell growth occurred if the methoxy substituent is placed at the C6 position, whereas C7 substitution decreases potency. The most promising compound in this series is 2-(3',4',5'-trimethoxybenzoyl)-3-methyl-5-amino-6-methoxybenzo[b]furan (3 h), which inhibits cancer cell growth at nanomolar concentrations (IC(50) =16-24 nM), and interacts strongly with tubulin by binding to the colchicine site. Sub-G(1) apoptotic cells in cultures of HL-60 and U937 cells were observed by flow cytometric analysis after treatment with 3 h in a concentration-dependent manner. We also show that compound 3 h induces apoptosis by activation of caspase-3, -8, and -9, and this is associated with cytochrome c release from mitochondria. The introduction of an α-bromoacryloyl group increased antiproliferative activity with respect to the parent amino derivatives.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21805646      PMCID: PMC3190670          DOI: 10.1002/cmdc.201100279

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  50 in total

Review 1.  Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin.

Authors:  Ernest Hamel
Journal:  Cell Biochem Biophys       Date:  2003       Impact factor: 2.194

Review 2.  Caspases: keys in the ignition of cell death.

Authors:  Jean-Bernard Denault; Guy S Salvesen
Journal:  Chem Rev       Date:  2002-12       Impact factor: 60.622

3.  Structural requirements for the interaction of combretastatins with tubulin: how important is the trimethoxy unit?

Authors:  Keira Gaukroger; John A Hadfield; Nicholas J Lawrence; Steven Nolan; Alan T McGown
Journal:  Org Biomol Chem       Date:  2003-09-07       Impact factor: 3.876

Review 4.  Microtubules as a target for anticancer drugs.

Authors:  Mary Ann Jordan; Leslie Wilson
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

5.  Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.

Authors:  Raimond B G Ravelli; Benoît Gigant; Patrick A Curmi; Isabelle Jourdain; Sylvie Lachkar; André Sobel; Marcel Knossow
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

6.  Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene and derived amino acid amides.

Authors:  George R Pettit; Collin R Anderson; Delbert L Herald; M Katherine Jung; Debbie J Lee; Ernest Hamel; Robin K Pettit
Journal:  J Med Chem       Date:  2003-02-13       Impact factor: 7.446

7.  Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.

Authors:  Italo Beria; Pier Giovanni Baraldi; Paolo Cozzi; Marina Caldarelli; Cristina Geroni; Sergio Marchini; Nicola Mongelli; Romeo Romagnoli
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

Review 8.  Cytochrome C-mediated apoptosis.

Authors:  Xuejun Jiang; Xiaodong Wang
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

9.  Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700).

Authors:  K Hori; S Saito
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.

Authors:  K Hori; S Saito
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  3 in total

1.  Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Filippo Prencipe; Carlota Lopez-Cara; Riccardo Rondanin; Daniele Simoni; Ernest Hamel; Stefania Grimaudo; Rosaria Maria Pipitone; Maria Meli; Manlio Tolomeo
Journal:  Eur J Med Chem       Date:  2015-11-27       Impact factor: 6.514

2.  Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Maria Kimatrai Salvador; Filippo Prencipe; Carlota Lopez-Cara; Santiago Schiaffino Ortega; Andrea Brancale; Ernest Hamel; Ignazio Castagliuolo; Stefania Mitola; Roberto Ronca; Roberta Bortolozzi; Elena Porcù; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2015-03-26       Impact factor: 7.446

3.  VDAC1: from structure to cancer therapy.

Authors:  Varda Shoshan-Barmatz; Dario Mizrachi
Journal:  Front Oncol       Date:  2012-11-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.